Company profile for Neovasc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neovasc is a leader in the development of minimally invasive therapies for two of the most vexing challenges in cardiovascular care: refractory angina and mitral valve regurgitation. The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in t...
Neovasc is a leader in the development of minimally invasive therapies for two of the most vexing challenges in cardiovascular care: refractory angina and mitral valve regurgitation. The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in treating advanced heart disease. Reducer is CE-marked for use in the EU and is FDA approved for investigational use in the US.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
13562 Maycrest Way #5138 Richmond, BC V6V 2J7
Telephone
Telephone
1.604.270.4344
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/revopsis-secures-16-5-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-neovascular-amd-treatment-302127081.html

PR NEWSWIRE
25 Apr 2024

https://www.globenewswire.com/news-release/2023/04/11/2644361/0/en/Shockwave-Medical-Completes-Acquisition-of-Neovasc.html

GLOBENEWSWIRE
11 Apr 2023

https://www.globenewswire.com/news-release/2023/03/31/2639027/0/en/Neovasc-Announces-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
31 Mar 2023

https://www.globenewswire.com/news-release/2023/03/06/2621604/0/en/Neovasc-Shareholders-Approve-Acquisition-by-Shockwave-Medical.html

GLOBENEWSWIRE
06 Mar 2023

https://www.globenewswire.com/news-release/2023/02/01/2599595/0/en/Neovasc-Announces-German-Reimbursement-Renewal.html

GLOBENEWSWIRE
01 Feb 2023

https://www.globenewswire.com/news-release/2023/01/17/2589887/0/en/Shockwave-Medical-Announces-Agreement-to-Acquire-Neovasc.html

GLOBENEWSWIRE
17 Jan 2023

ABOUT THIS PAGE

Contact Neovasc and get a quotation

Neovasc is a supplier offers 2 products (APIs, Excipients or Intermediates).

Find a price of Hydrochloric Acid bulk with JDMF offered by Neovasc

Find a price of Bovine Serum bulk offered by Neovasc

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty